HAEMATOLOGY CPD EDUCATION
Myelofibrosis: Update on diagnosis, risk stratification, and management
Optimise myelofibrosis management with practical guidance on patient stratification, JAK inhibitor therapy, and AHSCT referral.
Suitable for RACP CPD categories 1 and 2.
A supported CPD program
Online + in-practice
Learning Outcomes
By the completion of the course, you will be able to:
-
Apply contemporary prognostic scoring systems to accurately stratify patients with myelofibrosis into risk categories to inform treatment decisions.
-
Formulate an individualised management plan for a patient with intermediate- or high-risk myelofibrosis, justifying the selection and initial dosing of a PBS-listed JAK inhibitor based on patient-specific factors.
-
Evaluate the suitability of patients with high-risk myelofibrosis for allogeneic hematopoietic stem cell transplant (AHSCT)
-
Differentiate between prefibrotic and overtly fibrotic primary myelofibrosis and articulate the potential impact of the disease on a patient's quality of life.
Steering committee
Continuing Professional Development (CPD) Details
This medical education program may contribute to a healthcare professional's ongoing CPD requirements.
Category 1 | Educational Activities (EA): 1 hour*
Interactive, online module. Complete at your own pace.
Category 2 | Reviewing Performance (RP): 1 hour*
A online questionnaire to reflect on your current practice.
Please note that any additional reading or learning connected to this activity can be self recorded with your CPD body.
* Hours are estimates only and clinicians may choose to self-report CPD hours with their CPD home for each category at their own discretion.
Interested in a supported Patient Identification Program?
Maximise the impact of your patient identification framework with the support of a highly experienced Wellness Clinical Services Nurse Educator. Complete the form below and the team will be in touch to assess your eligibility for in-clinic or virtual support.
If you have questions regarding Praxhub's collection or use of your information, please visit our Terms of Use or contact privacy@praxhub.com
Nov 2025 AU-29028
About this education
This module provides a comprehensive update on the diagnosis, risk stratification, and management of myelofibrosis, tailored for the practising haematologist. Delve into the key aspects of myelofibrosis, from pathophysiology and driver mutations to the significant impact of the disease on patient quality of life. This module focuses on practical clinical application, providing detailed guidance on the diagnostic workup, the use of contemporary prognostic scoring systems, and the formulation of risk-adapted treatment plans.
You will refine your skills in selecting, dosing, and managing PBS-listed JAK inhibitors based on individual patient profiles, including anaemia and platelet counts. The module provides clear criteria for identifying and referring appropriate high-risk patients for allogeneic stem cell transplantation - the only potentially curative therapy. This activity will equip you with the confidence and knowledge to navigate the complexities of myelofibrosis and optimise outcomes for your patients.
